PET developer CompañĂa Mexicana de RadiologĂa (CMR) Naviscan is highlighting clinical results regarding positron emission mammography (PEM) published September 2 in European Radiology.
The study conducted at A.C.Camargo Cancer Center in SĂŁo Paulo included 40 patients and found that PEM identified all invasive carcinomas and high-grade ductal carcinomas in situ (DCIS). It had a sensitivity of 93.3%, specificity of 96%, and accuracy of 95%, the company said.
